Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Ayodele, O
    • Other Affiliation: Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, MA, United States
  • Ren, K
    • Other Affiliation: Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, MA, United States
  • Zhao, J
    • Other Affiliation: Analysis Group, Data Sciences Institute, Boston, MA, United States
  • Signorovitch, J
    • Other Affiliation: Analysis Group, Data Sciences Institute, Boston, MA, United States
  • Funk, M.J
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Zhu, J
    • Other Affiliation: Center for Observational Research and Data Science, Bristol-Myers Squibb, Princeton, NJ, United States
  • Bao, Y
    • Other Affiliation: Center for Observational Research and Data Science, Bristol-Myers Squibb, Princeton, NJ, United States
  • Gondek, K
    • Other Affiliation: Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, MA, United States
  • Keenan, H
    • Other Affiliation: Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, MA, United States
Abstract
  • The objective of this retrospective cohort study was to describe pre-treatment characteristics, treatment patterns, health resource use, and clinical outcomes among adults hospitalized with COVID-19 in the United States (US) who initiated common treatments for COVID-19. The Optum® COVID-19 electronic health records database was used to identify patients >18 years, diagnosed with COVID-19, who were admitted to an inpatient setting and received treatments of interest for COVID-19 between September 2020 and January 2021. Patients were stratified into cohorts based on index treatment use. Patient demographics, medical history, care setting, medical procedures, subsequent treatment use, patient disposition, clinical improvement, and outcomes were summarized descriptively. Among a total of 26,192 patients identified, the most prevalent treatments initiated were dexamethasone (35.4%) and dexamethasone + remdesivir (14.9%), and dexamethasone was the most common subsequent treatment. At day 14 post-index, <10% of patients received any treatments of interest. Mean (standard deviation [SD]) patient age was 65.6 (15.6) years, and the most prevalent comorbidities included hypertension (44.8%), obesity (35.4%), and diabetes (25.7%). At the end of follow-up, patients had a mean (SD) 8.1 (6.6) inpatient days and 1.4 (4.1) days with ICU care. Oxygen supplementation, non-invasive, or invasive ventilation was required by 4.5%, 3.0%, and 3.1% of patients, respectively. At the end of follow-up, 84.2% of patients had evidence of clinical improvement, 3.1% remained hospitalized, 83.8% were discharged, 4% died in hospital, and 9.1% died after discharge. Although the majority of patients were discharged alive, no treatments appeared to alleviate the inpatient morbidity and mortality associated with COVID-19. This highlights an unmet need for effective treatment options for patients hospitalized with COVID-19.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
License
  • Attribution 4.0 International
Journal title
  • PLoS ONE
Journal volume
  • 16
Journal issue
  • 12-Dec
Language
  • English
Version
  • Publisher
ISSN
  • 1932-6203
Publisher
  • Public Library of Science

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details journal.pone.0261707.pdf 2024-03-18 Public Download